Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

O W Press; J F Eary; F R Appelbaum; P J Martin; W B Nelp; S Glenn; D R Fisher; B Porter; D C Matthews; T Gooley

doi:10.1016/s0140-6736(95)92225-3

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

Identifier:nobleid.org/w1/20260515/80AFFC46

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/80AFFC46.svg?ark=w1%2F20260515%2F80AFFC46)](https://nobleid.org/work/w1/20260515/80AFFC46)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

Identifier:nobleid.org/w1/20260515/80AFFC46

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/80AFFC46.svg?ark=w1%2F20260515%2F80AFFC46)](https://nobleid.org/work/w1/20260515/80AFFC46)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work